GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Protagenic Therapeutics PTIX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.54

+0.52%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Protagenic Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Protagenic Therapeutics is based in New York, New York and is incorporated in Delaware. Its shares trade on OTC under the ticker PTIX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 March 2026, it reported revenue of $0 and net income of $1.4m. At that date it held total assets of $3.7m and shareholders' equity of $2.6m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
18 Dec 1996
Head office
149 FIFTH AVENUE, NEW YORK, NY, 10010
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Colin StottDirector, since 2025
  • Mr. Brian CorveseIndependent Director
  • Mr. Timothy WrightIndependent Director
  • Dr. Garo ArmenExecutive Chairman of the Board, since 2016$108,684
  • Mr. William NicholsPresident
  • Dr. Alexander ArrowChief Financial Officer$182,605
  • Dr. Andrew SleeChief Development Officer
  • Dr. Robert SteinChief Medical Officer, since 2016
  • Ms. Jennifer ChaoDirector
  • Mr. Barrett EvansDirector, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • PT00114 is a 41-residue peptide synthetic TCAP-1 with preclinical efficacy in depression models.
  • Protagenic Therapeutics focuses on stress-related neuropsychiatric disorders with a lead compound.
  • The company's portfolio includes neuropeptides targeting the TCAP pathway in preclinical evaluation.

Weaknesses

  • PT00114 has not yet demonstrated clinical efficacy in human trials.
  • The company's lead compound remains in preclinical stages without regulatory approval.
  • Protagenic Therapeutics has no marketed products or revenue streams from therapeutics.

Opportunities

  • PT00114 shows preclinical efficacy in opioid withdrawal models like the Saleens test.
  • The company can expand its neuropeptide portfolio targeting the TCAP pathway.
  • Growing demand for treatments for depression, anxiety, and PTSD presents opportunities.

Threats

  • Competition from other biotechnology firms in the neuropsychiatric disorder space.
  • Regulatory hurdles may delay clinical trials for PT00114 and other compounds.
  • Financial risks associated with prolonged preclinical development phases.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.